Literature DB >> 19958940

Tertiary hyperparathyroidism: is less than a subtotal resection ever appropriate? A study of long-term outcomes.

Susan C Pitt1, Rajarajan Panneerselvan, Herbert Chen, Rebecca S Sippel.   

Abstract

BACKGROUND: Our aim was to examine the outcomes of patients with tertiary hyperparathyroidism (3-HPT) who had limited resection of 1 or 2 parathyroids.
METHODS: We reviewed 140 patients with 3-HPT who underwent parathyroidectomy (PTX) at a single institution. Patients were analyzed according to their operation-limited PTX versus subtotal or total PTX.
RESULTS: The limited PTX group consisted of 29 patients who underwent resection of 1 (n = 12) or 2 (n = 17) parathyroids. The other 111 patients had subtotal (n = 104), total (n = 3), and/or reoperative PTX (n = 12). The mean +/- SEM follow-up was 79 +/- 5 months. Eucalcemia was achieved in 94% of the patients. All patients with persistent (n = 2) hypercalcemia underwent subtotal PTX (P = not significant [NS] vs limited PTX). In a logistic regression model, the extent of operation was not associated with the development of recurrent disease. Additionally, the incidence of permanent hypocalcemia was 7% after subtotal or total PTX versus 0% after limited resection (P = NS).
CONCLUSION: Long-term outcomes in patients with 3-HPT appear to be similar after appropriate limited resection of 1 or 2 parathyroid glands compared to subtotal or total PTX. Therefore, a strategy of limited parathyroid resection seems appropriate for patients with 3-HPT when the disease is limited to 1 or 2 glands.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19958940      PMCID: PMC2861425          DOI: 10.1016/j.surg.2009.09.026

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  17 in total

1.  Secondary and tertiary hyperparathyroidism: causes of recurrent disease after 446 parathyroidectomies.

Authors:  G Gasparri; M Camandona; G C Abbona; M Papotti; A Jeantet; E Radice; B Mullineris; M Dei Poli
Journal:  Ann Surg       Date:  2001-01       Impact factor: 12.969

2.  K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.

Authors: 
Journal:  Am J Kidney Dis       Date:  2003-10       Impact factor: 8.860

3.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

4.  Tertiary hyperparathyroidism after renal transplantation.

Authors:  J Nieto; P Ruiz-Cuevas; A Escuder; J Regas; L Callis
Journal:  Pediatr Nephrol       Date:  1997-02       Impact factor: 3.714

5.  Long-term follow-up of patients with tertiary hyperparathyroidism treated by resection of a single or double adenoma.

Authors:  Peter F Nichol; James R Starling; Eberhard Mack; Jason J Klovning; Bryan N Becker; Herbert Chen
Journal:  Ann Surg       Date:  2002-05       Impact factor: 12.969

6.  Tertiary hyperparathyroidism after renal transplantation: operative indications.

Authors:  A M D'Alessandro; J S Melzer; J D Pirsch; H W Sollinger; M Kalayoglu; W B Vernon; F O Belzer; J R Starling
Journal:  Surgery       Date:  1989-12       Impact factor: 3.982

7.  Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration.

Authors:  Herwig-Ulf Meier-Kriesche; Bettina J Steffen; Alan M Hochberg; Robert D Gordon; Michael N Liebman; Jonathan A Morris; Bruce Kaplan
Journal:  Transplantation       Date:  2003-04-27       Impact factor: 4.939

8.  Tertiary hyperparathyroidism: histologic patterns of disease and results of parathyroidectomy.

Authors:  Electron Kebebew; Quan-Yang Duh; Orlo H Clark
Journal:  Arch Surg       Date:  2004-09

9.  Radioguided parathyroidectomy in patients with secondary and tertiary hyperparathyroidism.

Authors:  Peter F Nichol; Eberhard Mack; Jesus Bianco; Allen Hayman; James R Starling; Herbert Chen
Journal:  Surgery       Date:  2003-10       Impact factor: 3.982

10.  Clinical and operative management of persistent hyperparathyroidism after renal transplantation: a single-center experience.

Authors:  Hanna Gilat; Raphael Feinmesser; Yanush Vinkler; Sara Morgenstern; Jacob Shvero; Gideon Bachar; Thomas Shpitzer
Journal:  Head Neck       Date:  2007-11       Impact factor: 3.147

View more
  10 in total

Review 1.  The surgical management of renal hyperparathyroidism.

Authors:  Catherine Madorin; Randall P Owen; William D Fraser; Phillip K Pellitteri; Brian Radbill; Alessandra Rinaldo; Raja R Seethala; Ashok R Shaha; Carl E Silver; Matthew Y Suh; Barrie Weinstein; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-11-20       Impact factor: 2.503

Review 2.  Surgical management of secondary hyperparathyroidism in chronic kidney disease--a consensus report of the European Society of Endocrine Surgeons.

Authors:  Kerstin Lorenz; Detlef K Bartsch; Juan J Sancho; Sebastien Guigard; Frederic Triponez
Journal:  Langenbecks Arch Surg       Date:  2015-10-02       Impact factor: 3.445

3.  Preoperative Imaging in Renal Transplant Patients with Tertiary Hyperparathyroidism.

Authors:  Megan G Berger; T K Pandian; Melanie L Lyden; Travis McKenzie; Matthew T Drake; Benzon M Dy
Journal:  World J Surg       Date:  2021-03-27       Impact factor: 3.352

4.  Radioguided parathyroidectomy for tertiary hyperparathyroidism.

Authors:  Yash R Somnay; Eric Weinlander; Amal Alfhefdi; David Schneider; Rebecca S Sippel; Herbert Chen
Journal:  J Surg Res       Date:  2015-02-19       Impact factor: 2.192

5.  Impact of parathyroidectomy on kidney graft function in post-transplant tertiary hyperparathyroidism: a comparative study.

Authors:  Samuel Frey; Thomas Goronflot; Claire Blanchard; Clarisse Kerleau; Pierre-Antoine Gourraud; Matthieu Wargny; Cécile Caillard; Maryvonne Hourmant; Lucile Figueres; Éric Mirallié
Journal:  Langenbecks Arch Surg       Date:  2022-05-21       Impact factor: 2.895

Review 6.  Parathyroid scintigraphy in renal hyperparathyroidism: the added diagnostic value of SPECT and SPECT/CT.

Authors:  David Taïeb; Pablo Ureña-Torres; Paolo Zanotti-Fregonara; Domenico Rubello; Alice Ferretti; Ioline Henter; Jean-François Henry; Francesca Schiavi; Giuseppe Opocher; Johan G Blickman; Patrick M Colletti; Elif Hindié
Journal:  Clin Nucl Med       Date:  2013-08       Impact factor: 7.794

7.  Characteristics of Persistent Hyperparathyroidism After Renal Transplantation.

Authors:  Takayuki Yamamoto; Yoshihiro Tominaga; Manabu Okada; Takahisa Hiramitsu; Makoto Tsujita; Norihiko Goto; Shunji Narumi; Yoshihiko Watarai
Journal:  World J Surg       Date:  2016-03       Impact factor: 3.352

Review 8.  [Endocrine surgery during and after the COVID-19 epidemic: Guidelines from AFCE].

Authors:  G Baud; L Brunaud; J C Lifante; C Tresallet; F Sebag; J P Bizard; M Mathonnet; F Menegaux; R Caiazzo; É Mirallié; F Pattou
Journal:  J Chir Visc       Date:  2020-04-30

9.  Prevalence and risk factors for tertiary hyperparathyroidism in kidney transplant recipients.

Authors:  Whitney Sutton; Xiaomeng Chen; Palak Patel; Shkala Karzai; Jason D Prescott; Dorry L Segev; Mara McAdams-DeMarco; Aarti Mathur
Journal:  Surgery       Date:  2021-07-12       Impact factor: 3.982

Review 10.  Mineral and Bone Disorders After Kidney Transplantation.

Authors:  Chandan Vangala; Jenny Pan; Ronald T Cotton; Venkat Ramanathan
Journal:  Front Med (Lausanne)       Date:  2018-07-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.